• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Pembrolizumab plus cetuximab shows early clinical efficacy for patients with recurrent or metastatic head and neck squamous cell carcinoma

byTeddy Guo
July 15, 2021
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

Click to read the study in The Lancet Oncology.

RELATED REPORTS

Camrelizumab may be safe and effective in the management of locally advanced esophageal squamous cell carcinoma

2 Minute Medicine Rewind March 16, 2026

Pembrolizumab improves survival in locally advanced head and neck cancer

Tags: esophageal squamous cell carcinomahead and neck cancerhead and neck squamous cell carcinomahead and neck squamous cell carcinoma (HNSCC)laryngeal cancernasopharyngeal cancernasopharyngeal carcinomaoral HPVoropharyngeal canceroropharyngeal carcinomaoropharyngeal squamous cell carcinomasquamous cell carcinoma
Previous Post

Combination therapy using conformation-specific KIT inhibitors associated with clinical benefit in patients with advanced gastrointestinal stromal tumors

Next Post

#VisualAbstract: Isatuximab improves progression-free survival in patients receiving carfilzomib–dexamethasone treatment for multiple myeloma

RelatedReports

Hybrid minimally invasive esophagectomy associated with lower complication rates compared to open esophagectomy
Chronic Disease

Camrelizumab may be safe and effective in the management of locally advanced esophageal squamous cell carcinoma

March 19, 2026
Buccal administration of dextrose gel effective for neonatal hypoglycemia
Weekly Rewinds

2 Minute Medicine Rewind March 16, 2026

March 16, 2026
Elective neck dissection may be unnecessary for adenoid cystic carcinoma
Oncology

Pembrolizumab improves survival in locally advanced head and neck cancer

August 26, 2025
#VisualAbstract: Neoadjuvant and Adjuvant Pembroli-zumab Increased Survival in Locally Advanced Head and Neck Cancer
StudyGraphics

#VisualAbstract: Neoadjuvant and Adjuvant Pembroli-zumab Increased Survival in Locally Advanced Head and Neck Cancer

July 18, 2025
Next Post
#VisualAbstract: Isatuximab improves progression-free survival in patients receiving carfilzomib–dexamethasone treatment for multiple myeloma

#VisualAbstract: Isatuximab improves progression-free survival in patients receiving carfilzomib–dexamethasone treatment for multiple myeloma

#VisualAbstract: Improved sleep quality reduced cardio-metabolic risk factors

#VisualAbstract: Improved sleep quality reduced cardio-metabolic risk factors

#VisualAbstract: Systematic analysis of tobacco smoking prevalence in 204 countries from 1990 to 2019

#VisualAbstract: Systematic analysis of tobacco smoking prevalence in 204 countries from 1990 to 2019

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cognitive behaviour therapy may be superior to bright light therapy for insomnia in women with breast cancer undergoing chemotherapy
  • Looksmaxxing raises body dysmorphia concerns among adolescent males
  • A healthy lifestyle may reduce risk of infection in patients with type 2 diabetes
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.

2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in